Celemics, Inc.
Founded in 2010 and listed on KOSDAQ in 2020, Celemics is an NGS-based genomic analysis technology platform company that manufactures and sells Target Capture Kits and the BTSeq next-generation sequencing solution.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureCelemics, Inc. was founded on November 29, 2010 and listed on the KOSDAQ market on August 21, 2020 as an NGS (Next Generation Sequencing)-based genomic analysis technology platform company. Based on its core next-generation cloning technology, MSSIC (Massively Separated and Sequenc Identified Cloning), the company manufactures and sells Target Capture Kit products using next-generation gene capture technology and the BTSeq next-generation sequencing solution using molecular barcode-mediated whole-sequence analysis technology. Its main business is manufacturing Target Capture kits, the core reagent for Targeted Sequencing, and providing target gene analysis services using them, operated under CEO Kim Hyo-ki with an in-house corporate research institute covering DNA materials/reagent development, optical instrument/automation equipment development, microfluidics/semiconductor processes, and bioinformatics algorithm development.
Products & technology
- Target Capture KitCore reagent for targeted sequencing using next-generation gene capture technology
- BTSeqNext-generation sequencing solution using molecular barcode-mediated whole-sequence analysis technology
Companies in the same categoryPharma & CDMO
Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.
Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.
Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.
Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.
KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.
Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.
KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.
Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.
Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.
KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.
Founded and listed on KOSDAQ in 2015, Kolmar BioTech is a nonclinical CRO providing efficacy testing for anticancer and metabolic disease drug candidates.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition